



Introduction

by **Nathan De Valck**

In this August newsletter, we are proud to announce that Pharma.Aero has onboarded GlaxoSmithKline Biologicals as our fifth Pharma Shipper.

Pharma.Aero has kicked off 2 new projects: a new Airport-to-Airport Pharma Corridor Project 2.0 and Project Sunrays: a joint project between Pharma.Aero and TIACA. You can read all about them in our Project Update section below. You can also access the white paper of our three webinars themed “The impact of COVID-19 on the airfreight Life Science and MedTech industry”, which were held in May and June.

In this newsletter, you will also find the announcement of Pharma.Aero’s General Assembly in October 2020, as well as an interview with Mr. Lim Ching Kiat, Managing Director, Air Hub Development, Changi Airport Group.

Stay safe, enjoy this newsletter and stay connected!

Nathan De Valck
Chairman of Pharma.Aero

Members Update

Pharma.Aero has recently onboarded GlaxoSmithKline Biologicals as its fifth pharmaceutical shipper. GlaxoSmithKline (GSK) Biologicals is the Belgium-based human vaccine research arm of GlaxoSmithKline. The company is working to discover new vaccines and develop combined products to prevent infections at the origin of major global health issues. As a major pharmaceutical company, GSK Biologicals will bring strong strategic value to Pharma.Aero's projects.



Projects Update

Project “Airport-to-Airport Pharma Corridor 2.0”

After the Corridor Project 1.0 between Brussels Airport and Hong Kong International Airport, which brought forth valuable insights, Pharma.Aero is refining the initial set of pharma lane mapping protocols and will apply it to new air trade corridors.

As part of the “Airport-to-Airport Corridor 2.0” project, Miami International Airport and Brussels Airport are working together to map the pharma corridor between the two airports. The goal of this project is to apply and test the redesigned corridor mapping protocol to the lane operated by Amerijet. Our pharmaceutical shipper members are actively participating to support this project.

As a next step later this year, other strategic airports and members of Pharma.Aero are invited to express their interest to start up more pharma corridor mappings. Info sessions will be organised to share the details of this initiative.

Project “Sunrays”: joint project Pharma.Aero and TIACA: Guidelines for optimal COVID-19 vaccine transportation

The International Air Cargo Association (TIACA) and Pharma.Aero have joined forces to develop global guidance for the air cargo industry to enable optimal transportation of the COVID-19 vaccine. As pharmaceutical companies race to develop the COVID-19 vaccine, it is still unclear what impact the vaccine will have on the global air logistics supply chain. To address this challenge, the joint working group will collaborate with all the key industry stakeholders, to gain insight and recommendations. The aim is to provide the air cargo industry with more clarity on the demands, expectations and quality the supply chain requires for the transportation of the vaccines, including but not restricted to critical trade lanes, air cargo capacity, handling and storage, track and trace requirements, for the transportation of the vaccines. At the same time, shippers will gain more understanding about the capabilities of the various logistics players. This will ensure that once the vaccine is

available in the market, the air cargo industry will be ready to respond to the needs of the shippers and transport vaccines in optimal conditions to all corners of the globe.

White Paper Project “COVID-19 webinars Pharma.Aero”

In May and June 2020, Pharma.Aero, together with STAT Trade Times, held a series of 3 consecutive webinars themed “The impact of COVID-19 on the airfreight Life Science and MedTech industry”. Pharma.Aero is proud to distribute the White Paper titled “An executive summary on the short-term consequences and the new normal”. [Click here](#) to access the link online or scan the QR code.



Announcement General Assembly Pharma.Aero

In October 20, 2020, Pharma.Aero is planning to hold its General Assembly, which all Strategic and Full Members are invited to. Due to the ongoing COVID-19 situation, we have decided to organise it virtually to ensure the well-being of our members. We plan to set up a virtual General Assembly and a webinar which we will share about the ongoing projects and solicit future collaborative ideas and projects. By the end of September, you will receive your official invitation via mail.

Board Member in the spotlight

Your Company and position:

As the Managing Director of Air Hub Development in Changi Airport Group, my key responsibility is to work closely with airlines and industry players to grow Changi Airport’s passenger and cargo traffic and network.

Your relation to airfreight pharma:

Changi strives to be the preferred air pharma hub in the region, providing support to the development of Singapore’s biomedical industry, including quality and reliable distribution of their pharma products through our global air cargo network. Today, eight of the top ten pharmaceutical companies have facilities in Singapore, manufacturing four of the top ten drugs by global revenue.

Any interesting developments within your company in relation to airfreight pharma you want to share?

Changi Airport works closely with our air cargo community. Singapore is the first air cargo hub in Asia Pacific that forms a CEIV Pharma community. Now with over ten companies certified, Singapore has the largest CEIV Pharma community in the region, delivering the highest standards to the pharma industry. Several years ago, Changi Airport and our local

CEIV Pharma community formed the Pharma@Changi initiative, with the common objective to jointly pursue the best standards in pharmaceuticals handling, thereby positioning Singapore Changi Airport as a trusted and reliable pharma air cargo hub in the region.

Pharma.Aero membership

What is the added value that Pharma.Aero can bring to the pharma handling in our air cargo industry?

Pharma.Aero is a unique cross-industry collaboration of different stakeholders in the pharma and air cargo industry. Though our strategic membership in Pharma.Aero, Changi is able to forge closer contacts with global pharma manufacturers and key air cargo industry players. Our participation in the projects enables us to develop our thought leadership in quality and reliable air transportation of pharma.

We are also very privileged to be given the opportunity to co-lead the Digi 1.0 and 2.0 projects, and more recently, the opportunity to be part of Pharma.Aero's joint project with TIACA, in leading the global efforts to prepare the air cargo industry in the manufacturing and distribution of COVID-19 vaccines.

Board Position

What is your position in the Board of Directors of Pharma.Aero and what does it entail?

Changi Airport has recently been elected as the co-Vice Chairman, responsible for both internal and external communications of the organisation.



Mr. Lim Ching Kiat
*Managing Director,
Air Hub Development
Changi Airport Group*